Literature DB >> 19284973

Cross-complementation of Clostridium perfringens PLC and Clostridium septicum alpha-toxin mutants reveals PLC is sufficient to mediate gas gangrene.

Catherine L Kennedy1, Dena Lyras, Jackie K Cheung, Thomas J Hiscox, John J Emmins, Julian I Rood.   

Abstract

Clostridium perfringens and Clostridium septicum are the most common causes of clostridial myonecrosis or gas gangrene. Although they mediate a similar disease pathology, they elaborate functionally very different alpha-toxins. We used a reciprocal complementation approach to assess the contribution of the primary toxin of each species to disease and found that C. perfringens alpha-toxin (PLC) was able to mediate the gross pathology of myonecrosis even in a C. septicum background, although it could not induce vascular leukostasis. Conversely, while C. septicum alpha-toxin restored some virulence to a C. perfringens plc mutant, it was less active than in its native background.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19284973     DOI: 10.1016/j.micinf.2009.01.002

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  11 in total

Review 1.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

Review 2.  Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease.

Authors:  Francisco A Uzal; John C Freedman; Archana Shrestha; James R Theoret; Jorge Garcia; Milena M Awad; Vicki Adams; Robert J Moore; Julian I Rood; Bruce A McClane
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

3.  The CpAL quorum sensing system regulates production of hemolysins CPA and PFO to build Clostridium perfringens biofilms.

Authors:  Jorge E Vidal; Joshua R Shak; Adrian Canizalez-Roman
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

Review 4.  Gas gangrene in mammals: a review.

Authors:  Carlos A Oliveira Junior; Rodrigo O S Silva; Francisco C F Lobato; Mauricio A Navarro; Francisco A Uzal
Journal:  J Vet Diagn Invest       Date:  2020-02-21       Impact factor: 1.279

5.  Regulation of virulence by the RevR response regulator in Clostridium perfringens.

Authors:  Thomas J Hiscox; Anjana Chakravorty; Jocelyn M Choo; Kaori Ohtani; Tohru Shimizu; Jackie K Cheung; Julian I Rood
Journal:  Infect Immun       Date:  2011-03-14       Impact factor: 3.441

6.  Role of phospholipases in fungal fitness, pathogenicity, and drug development - lessons from cryptococcus neoformans.

Authors:  Julianne Teresa Djordjevic
Journal:  Front Microbiol       Date:  2010-11-11       Impact factor: 5.640

7.  The cysteine protease α-clostripain is not essential for the pathogenesis of Clostridium perfringens-mediated myonecrosis.

Authors:  Anjana Chakravorty; Milena M Awad; Thomas J Hiscox; Jackie K Cheung; Glen P Carter; Jocelyn M Choo; Dena Lyras; Julian I Rood
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

8.  Regulation of sialidase production in Clostridium perfringens by the orphan sensor histidine kinase ReeS.

Authors:  Thomas J Hiscox; Paul F Harrison; Anjana Chakravorty; Jocelyn M Choo; Kaori Ohtani; Tohru Shimizu; Jackie K Cheung; Julian I Rood
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

9.  The pore-forming α-toxin from clostridium septicum activates the MAPK pathway in a Ras-c-Raf-dependent and independent manner.

Authors:  Anjana Chakravorty; Milena M Awad; Jackie K Cheung; Thomas J Hiscox; Dena Lyras; Julian I Rood
Journal:  Toxins (Basel)       Date:  2015-02-10       Impact factor: 4.546

10.  The NEAT Domain-Containing Proteins of Clostridium perfringens Bind Heme.

Authors:  Jocelyn M Choo; Jackie K Cheung; Jessica A Wisniewski; David L Steer; Dieter M Bulach; Thomas J Hiscox; Anjana Chakravorty; A Ian Smith; David A Gell; Julian I Rood; Milena M Awad
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.